Cyrus picks CYR212 as clinical candidate for IgG-driven diseases
Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases…
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases…
Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and…
The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and…
Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in…
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), an approved therapy for generalized myasthenia gravis (gMG) that’s injected under the…
Soliris (eculizumab) effectively eased symptoms and reduced the need for other medications in adults with myasthenia gravis (MG)…
Harbour BioMed has submitted a new, revised version of a biologics license application (BLA) to China’s regulatory agency requesting…
Patients who received Vyvgart (efgartigimod alfa) as part of an expanded access program required more frequent dosing to treat…
Butyric acid from gut bacteria, or supplementation with its salt form butyrate, could become potential treatments for myasthenia gravis…
Many of the adults with generalized myasthenia gravis (gMG) who took part in ADAPT, a Phase 3 clinical study…
Get regular updates to your inbox.